Defining Predictors of RT Response to Vedolizumab in IBD
NCT03142321
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Crohn Disease of Small Intestine
Interventions
DRUG:
Vedolizumab 300 MG Injection [Entyvio]
Sponsor
Washington University School of Medicine